GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (FRA:37Z) » Definitions » Common Stock

Allakos (FRA:37Z) Common Stock : €0.08 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Allakos Common Stock?

Allakos's quarterly common stock increased from Jun. 2023 (€0.08 Mil) to Sep. 2023 (€0.08 Mil) but then declined from Sep. 2023 (€0.08 Mil) to Dec. 2023 (€0.08 Mil).

Allakos's annual common stock increased from Dec. 2021 (€0.05 Mil) to Dec. 2022 (€0.08 Mil) and increased from Dec. 2022 (€0.08 Mil) to Dec. 2023 (€0.08 Mil).


Allakos Common Stock Historical Data

The historical data trend for Allakos's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allakos Common Stock Chart

Allakos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial 0.04 0.04 0.05 0.08 0.08

Allakos Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.08 0.08 0.08 0.08

Allakos Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Allakos (FRA:37Z) Business Description

Traded in Other Exchanges
Address
825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

Allakos (FRA:37Z) Headlines

No Headlines